Accutar Biotechnology
's headquarters is located in Brooklyn, New York. Accutar Biotechnology's latest funding round was a Debt - PPP (CARES Act) for $150K on May 2020. Accutar Biotechnology's top competitor is Silicon Therapeutics , led by Lanny Sun, who is their Co-Founder & CEO. Accutar Biotechnology has 1 followers on Owler. Accutar Biotechnology has an estimated revenue of <$1M and an estimate of less <10 employees.Accutar Biotechnology
's headquarters is located in Brooklyn, New York. Accutar Biotechnology's latest funding round was a Debt - PPP (CARES Act) for $150K on May 2020. Accutar Biotechnology's top competitor is Silicon Therapeutics , led by Lanny Sun, who is their Co-Founder & CEO. Accutar Biotechnology has 1 followers on Owler. Accutar Biotechnology has an estimated revenue of <$1M and an estimate of less <10 employees.
CEO
Add
News
Aug 14, 2024
Business Wire
Press Release: Accutar Biotechnology : Accutar Biotechnology Receives FDA Fast Track Designation for AC699 in ER+ / HER2- Breast Cancer
Jun 03, 2024
Business Wire India
Press Release: Accutar Biotechnology : Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
Dec 05, 2023
Global Legal Chronicle
Accutar Biotechnology: Accutar Biotechnology's Collaboration with Evommune
Jun 21, 2023
Acrofan
Accutar Biotechnology: Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
Feb 23, 2023
ChinaBio Today
Accutar Biotechnology: Accutar Starts China Trial of Oral Chimeric Degrader for Prostate Cancer
Feb 23, 2023
Business Wire
Press Release: Accutar Biotechnology : Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer
Feb 06, 2023
Pharmabiz
Accutar Biotechnology: US FDA clears Accutar Biotechnology's IND application for phase 1 trial of AC0676 in Bcell malignancies
Oct 13, 2022
ChinaBio Today
Accutar Biotechnology: Accutar Starts China Phase I Trial of AI-developed Protein Degrader for Breast Cancer
Oct 11, 2022
StreetInsider
Press Release: Accutar Biotechnology : Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer
Jun 02, 2022
FirstWord Pharma
Accutar Biotechnology: Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Accutar Biotechnology Competitors
1
2
3
4
5
6
7
8
9
10